An Automatable Hydrogel Culture Platform for Evaluating Efficacy of Antibody-based Therapeutics in Overcoming Chemoresistance.

The microenvironment plays a major role in conferring chemoresistance to cancer cells. In order to better inform clinical response to chemoresistance, preclinical models that recapitulate its hallmark features are needed to enable screening for resistance-specific therapeutic targets. A novel platform for seeding cancer cells in 3D hydrogels is presented utilizing derivatives of chitosan and alginate that, critically, is amenable to high throughput screening: cell seeding in hydrogels, media changes, dosing of anticancer compounds, and cell viability assays were all automated using a standard and commercially available liquid handling robot. Culture in these hydrogels elicits resistance in ovarian, lung, and prostate cancer cells to treatment by doxorubicin and paclitaxel. In correlation, proteomics analysis of SKOV3 cells cultured in 3D revealed enrichment of proteins associated with extreme drug resistance (EDR) including HMOX1 and ALDH2. Subsequently, therapeutic antibodies targeted to tumor-associated antigens upregulated in 3D cultures were shown to have higher efficacy compared to 2D cultures. Collectively, this automated 3D cell culture platform provides a powerful tool with utility in identification of drugs that may overcome chemoresistance. This article is protected by copyright. All rights reserved.

[1]  Forrest M Kievit,et al.  Proliferation and enrichment of CD133(+) glioblastoma cancer stem cells on 3D chitosan-alginate scaffolds. , 2014, Biomaterials.

[2]  K. Baggerly,et al.  Autocrine Effects of Tumor-Derived Complement , 2014, Cell reports.

[3]  Stephen J. Florczyk,et al.  Chitosan-Alginate Scaffold Culture System for Hepatocellular Carcinoma Increases Malignancy and Drug Resistance , 2010, Pharmaceutical Research.

[4]  E. D. de Vries,et al.  Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. , 2019, The Lancet. Oncology.

[5]  B. Teicher,et al.  Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. , 1990, Science.

[6]  B. Maria,et al.  CD147-dependent heterogeneity in malignant and chemoresistant properties of cancer cells. , 2013, The American journal of pathology.

[7]  M. Briehl,et al.  Lymphoma cells with increased anti-oxidant defenses acquire chemoresistance. , 2012, Experimental and therapeutic medicine.

[8]  F. Bertucci,et al.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.

[9]  L. Shaw,et al.  Integrin (α6β4) regulation of eIF-4E activity and VEGF translation , 2002, The Journal of Cell Biology.

[10]  Ursula Graf-Hausner,et al.  An in vitro osteosarcoma 3D microtissue model for drug development. , 2014, Journal of biotechnology.

[11]  K. Marra,et al.  Injectable in situ forming biodegradable chitosan-hyaluronic acid based hydrogels for cartilage tissue engineering. , 2009, Biomaterials.

[12]  Andrea Urbani,et al.  A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines. , 2009, Biochimica et biophysica acta.

[13]  Apurva R. Patel,et al.  AlgiMatrix™ Based 3D Cell Culture System as an In-Vitro Tumor Model for Anticancer Studies , 2013, PloS one.

[14]  T. Fan,et al.  Glycolytic reprogramming through PCK2 regulates tumor initiation of prostate cancer cells , 2017, Oncotarget.

[15]  H. Lane,et al.  ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.

[16]  M. Mann,et al.  Universal sample preparation method for proteome analysis , 2009, Nature Methods.

[17]  David J Mooney,et al.  Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution. , 2005, Biomaterials.

[18]  Lung-Ji Chang,et al.  The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance. , 2012, Chemico-biological interactions.

[19]  E. Lengyel,et al.  A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. , 2011, Gynecologic oncology.

[20]  G. Lajoie,et al.  Matrigel: A complex protein mixture required for optimal growth of cell culture , 2010, Proteomics.

[21]  T. Matsushita,et al.  Enhancement of drug efflux activity via MDR1 protein by spheroid culture of human hepatic cancer cells. , 2011, Journal of bioscience and bioengineering.

[22]  T. Wilson,et al.  Chemoresistance in solid tumours. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  T. Groth,et al.  Bioactivity of immobilized hyaluronic acid derivatives regarding protein adsorption and cell adhesion , 2011, Biotechnology and applied biochemistry.

[24]  A. Tomida,et al.  Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. , 1999, Anti-cancer drug design.

[25]  M. Zenobi‐Wong,et al.  Engineered Microtissues Formed by Schiff Base Crosslinking Restore the Chondrogenic Potential of Aged Mesenchymal Stem Cells , 2015, Advanced healthcare materials.

[26]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[27]  Robert A. Gatenby,et al.  Environment-mediated drug resistance: a major contributor to minimal residual disease , 2009, Nature Reviews Cancer.

[28]  T. Fan,et al.  Glycolytic reprogramming through PCK2 regulates tumor initiation of prostate cancer cells. , 2017, Oncotarget.

[29]  Chunfu Wu,et al.  Targeting ALDH2 with disulfiram/copper reverses the resistance of cancer cells to microtubule inhibitors , 2018, Experimental cell research.

[30]  K. Schwarz,et al.  Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. , 2007, Cancer research.

[31]  C. Staedel,et al.  Altered adhesion properties and alpha v integrin expression in a cisplatin‐resistant human ovarian carcinoma cell line , 2002, International journal of cancer.

[32]  Michelle R. Dawson,et al.  Alterations in Ovarian Cancer Cell Adhesion Drive Taxol Resistance by Increasing Microtubule Dynamics in a FAK-dependent Manner , 2015, Scientific Reports.

[33]  Ali Khademhosseini,et al.  In vitro and in vivo analysis of visible light crosslinkable gelatin methacryloyl (GelMA) hydrogels. , 2017, Biomaterials science.

[34]  Dietmar W. Hutmacher,et al.  Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. , 2010, Biomaterials.

[35]  T. Kijima,et al.  Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis , 2013, Scientific Reports.

[36]  Daniel W Chan,et al.  Suppression of annexin A11 in ovarian cancer: implications in chemoresistance. , 2009, Neoplasia.

[37]  Alastair H Kyle,et al.  Limited Tissue Penetration of Taxanes: A Mechanism for Resistance in Solid Tumors , 2007, Clinical Cancer Research.

[38]  Stephen J. Florczyk,et al.  Chitosan-alginate 3d Scaffolds as a Mimic of the Glioma Tumor Microenvironment , 2022 .

[39]  David L. Kaplan,et al.  Enzymatically crosslinked silk-hyaluronic acid hydrogels. , 2017, Biomaterials.

[40]  Charlotte Kuperwasser,et al.  Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy , 2008, Breast Cancer Research.